| Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management S Shimony, M Stahl, RM Stone American Journal of Hematology 98 (3), 502-526, 2023 | 262 | 2023 |
| Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML M Stahl, K Menghrajani, A Derkach, A Chan, W Xiao, J Glass, AC King, ... Blood advances 5 (5), 1552-1564, 2021 | 157 | 2021 |
| Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort M Stahl, M DeVeaux, P Montesinos, R Itzykson, EK Ritchie, MA Sekeres, ... Blood advances 2 (8), 923-932, 2018 | 142 | 2018 |
| Differentiation syndrome in acute promyelocytic leukaemia M Stahl, MS Tallman British journal of haematology 187 (2), 157-162, 2019 | 139 | 2019 |
| The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort M Stahl, M DeVeaux, T De Witte, J Neukirchen, MA Sekeres, AM Brunner, ... Blood advances 2 (14), 1765-1772, 2018 | 132 | 2018 |
| Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era? Y Liu, JP Bewersdorf, M Stahl, AM Zeidan Blood reviews 34, 67-83, 2019 | 122 | 2019 |
| Immune checkpoint inhibitors in acute myeloid leukemia: novel combinations and therapeutic targets M Stahl, AD Goldberg Current oncology reports 21, 1-10, 2019 | 108 | 2019 |
| Selecting initial treatment of acute myeloid leukaemia in older adults NA Podoltsev, M Stahl, AM Zeidan, SD Gore Blood reviews 31 (2), 43-62, 2017 | 106 | 2017 |
| Epigenetic therapy combinations in acute myeloid leukemia: what are the options? JP Bewersdorf, R Shallis, M Stahl, AM Zeidan Therapeutic advances in hematology 10, 2040620718816698, 2019 | 99 | 2019 |
| Epigenetics in cancer: a hematological perspective M Stahl, N Kohrman, SD Gore, TK Kim, AM Zeidan, T Prebet PLoS genetics 12 (10), e1006193, 2016 | 97 | 2016 |
| Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy KC Suozzi, M Stahl, CJ Ko, A Chiang, SN Gettinger, MD Siegel, ... JAAD case reports 2 (3), 264-268, 2016 | 97 | 2016 |
| Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all M Stahl, MS Tallman Leukemia & lymphoma 60 (13), 3107-3115, 2019 | 95 | 2019 |
| Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review … JP Bewersdorf, S Giri, R Wang, RT Williams, MS Tallman, AM Zeidan, ... Haematologica 105 (11), 2659, 2020 | 92 | 2020 |
| Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia W Xiao, A Chan, MR Waarts, T Mishra, Y Liu, SF Cai, J Yao, Q Gao, ... Blood, The Journal of the American Society of Hematology 137 (10), 1377-1391, 2021 | 84 | 2021 |
| Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short-and long-term clinical outcomes: a large, retrospective … M Stahl, RM Shallis, W Wei, P Montesinos, E Lengline, J Neukirchen, ... Leukemia 34 (12), 3149-3160, 2020 | 83 | 2020 |
| Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes AM Zeidan, U Platzbecker, JP Bewersdorf, M Stahl, L Adès, U Borate, ... Blood, The Journal of the American Society of Hematology 141 (17), 2047-2061, 2023 | 81 | 2023 |
| Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts AM Zeidan, PC Boddu, MM Patnaik, JP Bewersdorf, M Stahl, RK Rampal, ... The Lancet Haematology 7 (8), e601-e612, 2020 | 80 | 2020 |
| Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications M Stahl, AM Zeidan Cancer 123 (10), 1703-1713, 2017 | 65 | 2017 |
| Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation AM Zeidan, M Stahl, X Hu, R Wang, SF Huntington, NA Podoltsev, ... Blood, The Journal of the American Society of Hematology 131 (7), 818-821, 2018 | 60 | 2018 |
| Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis JP Bewersdorf, S Giri, R Wang, N Podoltsev, RT Williams, MS Tallman, ... Leukemia 35 (6), 1643-1660, 2021 | 58 | 2021 |
Amer Zeidan, MBBS, MHSProfessor of Medicine, Yale UniversityVerifierad e-postadress på yale.edu
